Cadrenal Therapeutics, Inc. (CVKD)
Nasdaq · Healthcare · Biotechnology
$0.9458−0.44%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.4M
- 52-week range
- $0.85 – $14.50
- 52-week change
- −93.10%
- EPS (trailing)
- −$4.91
Fiscal year to Dec 2025
- Net income
- −$13.2M
- Diluted EPS
- −$6.64
- Free cash flow
- −$12.6M
From the company’s annual report on SEC EDGAR.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Headquarters: Ponte Vedra, United States · 5 employees · cadrenal.com